Board Member
Opus Genetics, Inc. (IRD)Equibles does not estimate personal net worth.
Get an email with a short summary when Opus Genetics, Inc. publishes a filing, an earnings call transcript or a press release.
Get IRD alertsGeorge Magrath is recorded as CEO and Board Member at Opus Genetics, Inc. (IRD) since November 1, 2023. Opus Genetics, Inc. reported in an 8-K filed November 1, 2023 that George Magrath was appointed member of the Board, effective November 1, 2023. Opus Genetics, Inc. reported in an 8-K filed November 1, 2023 that George Magrath was appointed Chief Executive Officer, effective November 1, 2023. George Magrath has spoken on 2 investor events across 1 company, most recently for Opus Genetics, Inc. on October 20, 2026. Opus Genetics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Opus Genetics, Inc. includes Dr. George Magrath (CEO and Board Member), George Magrath, M.D., M.B.A., M.S. (CEO and Board Member), Richard Rodgers (CEO and Board Member) and 7 others.
“Dr. Magrath was also appointed as a member of the Board, effective as of November 1, 2023.”
“On October 30, 2023, the Board of Directors (the “Board”) of Ocuphire Pharma, Inc. (the “Company”) appointed Dr. George Magrath, age 39, as the Company’s Chief Executive Officer, effective as of November 1, 2023.”
“From a strategic standpoint, it's really interesting because it's going to be, well, it is now, the first approved presbyopia drop that does not have a warning label for potential of retinal detachment.”
“I mean, it's a great space to be in right now. A lot of activity in inherited retinal diseases.”
2023-11-01–present
2023-11-01–present
Biotechnology · Healthcare
CEO, Board Member
2023-11-01–present
